tirzepatide cardiovascular outcomes trial results july 2025 An Observational Study of of vs Glucagon-Like Peptide-1 Receptor Agonists 60-Second Journal Club: The SUMMIT

The Noom Microdose GLP-1 Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion

Krger N, Schneeweiss S, Desai RJ, et al

Conclusion Current literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal to moderateseverity AEs

, 2 , -

It requires a prescription from a licensed healthcare provider

In conclusion, tirzepatide is a highly effective medication for weight loss in clinical trials